Several preclinical studies have proved that osimertinib was active in specific lung cancer cell lines with EGFRex20ins mutations [26–29], while the clinical activity of the 3rd generation EGFR TKIs in EGFRex20ins tumors remains unknown. This evidence concerns the gene EGFR and lung cancer.